Nevro’s spinal cord stimulator earns CE mark

Nevro’s HFX iQ spinal cord stimulator earned the European Union’s CE mark, the company said Nov. 12.

Advertisement

HFX iQ has already earned FDA approval in 2022, according to a news release. The spinal cord stimulator uses artificial intelligence combined with high-frequency therapy to help patients with chronic pain. It is indicated for back and leg pain, non-surgical refractory back pain, painful diabetic neuropathy, chronic upper limb and neck pain.

The company plans to launch the system in select European countries in early 2025.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.